Business Context and Reporting Period
This Form 8-K is a current report filed by Oncocyte Corporation (not Insight Molecular Diagnostics Inc.) on July 13, 2023. The filing addresses an amendment to the employment agreement of Joshua Riggs, the Company's President and Chief Executive Officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation adjustments.
Material Changes
- Elimination of Performance Grant: On July 13, 2023, the Company and Mr. Riggs entered into an amendment to the 2023 Employment Agreement which eliminated the "Performance Grant" of options to purchase 800,000 shares of Common Stock.
- Retention of Base Compensation: The base salary of $360,000 per annum, the target bonus opportunity of 50% of base salary, and the "CEO Grant" of options to purchase 350,000 shares (subject to time-based vesting) remain in effect.
Guidance, Outlook, and Management Commentary
The Company intends to consider granting additional performance-based options to Mr. Riggs in the future, contingent upon shareholder approval of an amendment to the 2018 Equity Incentive Plan. This proposed amendment would eliminate the current limitation on the number of shares that can be granted to any individual participant during a one-year period. The terms of any such additional grant have not yet been determined by the Board of Directors or the Compensation Committee.
Investor Verification Checklist
- Verify the status of the proposed amendment to the 2018 Equity Incentive Plan regarding share grant limits.
- Confirm the exact vesting schedule and terms of the remaining 350,000 share "CEO Grant."
- Review the full text of the Amendment to the Employment Agreement filed as Exhibit 10.1 for any additional conditions.
- Monitor future filings for the potential issuance of new performance-based options pending shareholder approval.